OEHHA Acute, 8-hour and Chronic Reference Exposure Level (REL) Summary
All OEHHA Acute, 8-hour and Chronic Reference Exposure Levels (RELs)
Documentation available in the Air Toxics Hot Spots Program Guidance Manual for the Preparation of Health Risk Assessments 2015 (Appendices A, B and C)
OEHHA Acute, 8-hour and Chronic Reference Exposure Level (REL) Summary1 | |||||
|---|---|---|---|---|---|
Substance | REL type[1] | Inhalation REL | Oral REL | Hazard Index | Species[2] |
| Acetaldehyde (75-07-0) | A | 470[5] |
| Eyes; respiratory system (sensory irritation) | H |
8 | 300[4,5] |
| Respiratory system | R | |
C | 140[4,5] |
| Respiratory system | R | |
| Acrolein (107-02-8) | A | 2.5[5] |
| Eyes, respiratory system (sensory irritation) | H |
8 | 0.7[5] |
| Respiratory system | R | |
C | 0.35[5] |
| Respiratory system | R | |
| Acrylic Acid (79-10-7) | A | 6,000 | Respiratory system; eyes | R | |
| Acrylonitrile (107-13-1) | C | 5[4] |
| Respiratory system | R |
| Ammonia (7664-41-7) | A | 3200[4] | Respiratory system; eyes | H | |
C | 200 | Respiratory system | H | ||
| Arsenic (7440-38-2) & inorganic arsenic compounds (including arsine) | A | 0.20[5] |
| Development; cardiovascular system; nervous system | M |
8 | 0.015[5] |
| Development; cardiovascular system; nervous system; respiratory system; skin | H | |
C | 0.015[5] | 0.0035[5] | Inhalation & oral: Development; cardiovascular system; nervous system; respiratory system; skin | H | |
| Benzene (71-43-2) | A | 27 |
| Developmental; Immune system; Hematologic system | M |
8 | 3 |
| Hematologic system | H | |
C | 3 |
| Hematologic system | H | |
| Benzyl Chloride(100-44-7) | A | 240 |
| Respiratory system; eyes | M, R |
| Beryllium& beryllium compounds (7440-41-7) | C | 0.007 | 2.0 | Inhalation: Respiratory system; immune system Oral: Alimentary system (Gastrointestinal tract) | H |
| 1-Bromopropane (106-94-5) | A | 3300[4, 5] |
| Developmental | R |
8 | 3.4[5] |
| Nervous system; respiratory system | H | |
C | 1.7[5] |
| Nervous system; respiratory system | H | |
| Butadiene (106-99-0) | A | 660[4,5] | Development | M | |
8 | 9[4,5] | Reproductive system | M | ||
C | 2[4,5] |
| Reproductive system | M | |
| Cadmium & cadmium compounds (7440-43-9) | C | 0.02 | 0.5 | Inhalation: Kidney; respiratory system Oral: kidney | H |
| Carbon disulfide (75-15-0) | A | 6,200 | Reproductive/ Development; nervous system | R | |
C | 800[4] | Nervous system; reproductive system | H | ||
| Carbon monoxide (630-08-0) | A | 23,000 |
| Cardiovascular system | H |
| Carbonyl Sulfide (463-58-1) | A | 660[5] | Nervous system | R | |
8 | 10[4, 5] | Nervous system | R | ||
C | 10[4, 5] | Nervous system | R | ||
| Caprolactam (105-60-2) | A | 50 | Eyes (sensory irritation) | H | |
8 | 7 | Respiratory system | R | ||
C | 2.2 |
Respiratory system | R | ||
| Carbon tetrachloride (56-23-5) | A | 1,900 | Alimentary system (liver); Reproductive/ Developmental; nervous system | R | |
C | 40 | Alimentary and nervous systems; development | GP | ||
Chlorinated dibenzo-p dioxins and Unspeciated mixtures treated as 2,3,7,8-tetrachlorodibenzo-p-dioxin (1746-01-6) | C | 0.00004 | 1 x 10-5 | Inhalation and Oral: Alimentary (liver) reproductive, endocrine, respiratory, hematologic systems; development | R |
| Chlorine (7782-50-5) | A | 210 | Respiratory system; eyes | H | |
C | 0.2[4] | Respiratory system | R | ||
| Chlorine dioxide (10049-04-4) | C | 0.6 |
| Respiratory system | R |
| Chlorobenzene (108-90-7) | C | 1,000 |
| Alimentary system (liver); kidney; reproductive system | R |
| Chloroform (67-66-3) | A | 150 | Reproductive/ Developmental; respiratory system; nervous system | R | |
C | 300 | Alimentary system; kidney; development | R | ||
| Chloropicrin (76-06-2) | A | 29 | Respiratory system; eyes | M | |
C | 0.4[4] | Respiratory system | M | ||
| Chromic trioxide (as chromic acid mist) | C | 0.002 | 20 | Inhalation: Respiratory system Oral: Hematologic system | H |
| Chromium (hexavalent) (18540-29-9) & soluble hexavalent chromium compounds (except chromic trioxide) | C | 0.2[4] | 20 | Inhalation: Respiratory system Oral: Hematologic system | R |
| Chromium (trivalent) inorganic water-soluble compounds (Inhalation concentrations as µg Cr(III)/m3) | A | 0.48[5] |
| Respiratory system | Ha |
8 | 0.12[4,5] |
| Respiratory system | R | |
C | 0.06[4,5] |
| Respiratory system | R | |
| Copper and compounds | A | 100 |
| Respiratory system | H |
| Cresol mixtures (1319-77-3) | C | 600 |
| Nervous system | R |
| Dichlorobenzene (1,4-) (106-46-7) | A | 8,700 |
| Development | R |
8 | 10 |
| Respiratory system; Male Reproductive system | R, M | |
C | 5 |
| Respiratory system; Male Reproductive system | R, M | |
| Dichloroethylene (1,1) (75-35-4) | C | 70 |
| Alimentary system (liver) | GP |
| Diesel Exhaust | C | 5[3] |
| Respiratory system | R |
| Diethanolamine (111-42-2) | C | 3 |
| Respiratory and hematologic systems | R |
| Dimethylformamide (N,N-) (68-12-2) | C | 80 |
| Alimentary (liver) and respiratory systems | H |
| Dioxane (1,4-) (123-91-1) | A | 3,000 | Respiratory system; eyes | H | |
C | 3,000 | Alimentary system; kidney; cardiovascular system | R | ||
| Epichlorohydrin (106-89-8) | A | 1,300 | Respiratory system; eyes | H | |
C | 3 | Respiratory system; eyes | R | ||
| Epoxybutane (1,2-) (106-88-7) | C | 20 |
| Respiratory system; cardiovascular system | M |
| Ethylbenzene(100-41-4) | C | 2,000 |
| Alimentary system (liver); kidney; endocrine system; development | M, R |
| Ethyl chloride (75-00-3) | C | 30,000 |
| Development; alimentary system (liver) | M |
| Ethylene dibromide (106-93-4) | C | 0.8 |
| Reproductive system | H |
| Ethylene dichloride (107-06-2) | C | 400 |
| Alimentary system (liver) | R |
| Ethylene glycol (107-21-1) | C | 400 |
| Respiratory system; kidney; development | H |
| Ethylene glycol monobutyl ether (111-76-2) | A | 4700 |
| Eyes and respiratory system | H |
8 | 164 |
| Respiratory system | R | |
C | 82 |
| Respiratory system | R | |
| Ethylene glycol monoethyl ether acetate (111-15-9) | A | 140 | Reproductive/ Development; nervous system | R | |
C | 300 | Development | Rb | ||
| Ethylene glycol monomethyl ether (109-86-4) | A | 93 | Reproductive/ Development | R | |
C | 60 | Reproductive system | Rb | ||
| Ethylene glycol monomethyl ether acetate (110-49-6) | C | 90 |
| Reproductive system | Rb |
| Ethylene oxide (75-21-8) | C | 30 |
| Nervous system | R |
| Fluorides (except Hydrogen Fluoride - listed below separately) | C | 13[4] | 40 | Inhalation: Bone and teeth; respiratory system Oral: Bone and teeth | H |
| Formaldehyde (50-00-0) | A | 55[5] |
| Eyes (Sensory irritation) | H |
8 | 9[5] |
| Respiratory system | H | |
C | 9[5] |
| Respiratory system | H | |
| Glutaraldehyde (111-30-8) | C | 0.08[4] |
| Respiratory system | M |
Hexamethylene diisocyanate (monomer, 822-06-0) | A | 0.3[5] |
| Respiratory system | R |
8 | 0.06[5] |
| Respiratory system | H | |
C | 0.03[5] |
| Respiratory system | H | |
Hexamethylene diisocyanate (polyisocyanate mixtures, including, but not limited to isocyanurate (3779-63-3) and biuret (4035-89-6)) | A | 4.5[5] |
| Respiratory system | R |
8 | 0.8[5] |
| Respiratory system | R | |
C | 0.4[5] |
| Respiratory system | R | |
| Hexane (n-)(110-54-3) | C | 7000 |
| Nervous system | H |
| Hydrazine (302-01-2) | C | 0.2 |
| Alimentary system (liver); endocrine system | Ha |
| Hydrogen chloride (7647-01-0) | A | 2,100 | Respiratory system; eyes | H | |
C | 9 | Respiratory system | H | ||
| Hydrogen cyanide (74-90-8) | A | 340 | Nervous system | H | |
C | 9 | Nervous system; endocrine system; cardiovascular system | H | ||
| Hydrogen fluoride (7664-39-3) | A | 240 | Respiratory system; eyes | H | |
C | 14[4] | 40 | Inhalation: Bone and teeth; respiratory system (See “fluorides” summary) Oral: Bone and teeth | H | |
| Hydrogen selenide (7783-07-5) | A | 5 |
| Respiratory system; eyes | GP |
| Hydrogen sulfide (7783-06-4) | A | 42 | Nervous system | H | |
C | 10 | Respiratory system | M | ||
| Isophorone (78-59-1) | C | 2,000 |
| Development; alimentary system (liver) | R, M |
| Isopropanol (67-63-0) | A | 3,200 | Eyes; respiratory system | H | |
C | 7,000 | Kidney; development | R, M | ||
| Maleic anhydride (108-31-6) | C | 0.7[4] |
| Respiratory system | R,Ha, Mk |
| Manganese (7439-96-5) & manganese compounds | 8 | 0.17[4,5] |
| Nervous system | H |
C | 0.09[4,5] |
| Nervous system | H | |
| Mercury (7439-97-6) & inorganic mercury compounds | A | 0.6[5] |
| Nervous system; development | R |
8 | 0.06[5] |
| Nervous system; development; kidney | H | |
C | 0.03[5] | 0.16[5] | Inhalation & Oral: Nervous system; development; kidney | H | |
| Methanol (67-56-1) | A | 28,000 | Nervous system | H | |
C | 4,000[4] | Development | M | ||
| Methyl bromide (74-83-9) | A | 3900 | Nervous system; respiratory system; Reproductive/ development | H | |
C | 5 | Respiratory system; nervous system; development | R | ||
| Methyl chloroform (71-55-6) | A | 68,000 | Nervous system | H | |
C | 1000 | Nervous system | Gb | ||
| Methylene chloride (75-09-2) | A | 14,000 | Cardiovascular system; Nervous system | H | |
C | 400 | Cardiovascular system; nervous system | H | ||
| Methylene dianiline(4,4’-) (101-77-9) | C | 20 |
| Eyes; alimentary system (liver) | GP |
| Methylene diphenyl isocyanate (101-68-8) and polymeric methylene diphenyl diisocyanate (9016-87-9) | A | 12[5] | Respiratory system | R | |
| 8 | 0.16[5] | Respiratory system | R | ||
C | 0.08[5] |
| Respiratory system | R | |
| Methyl ethyl ketone (78-93-3) | A | 13,000 |
| Respiratory system; eyes | H |
| Methyl isocyanate (624-83-9) | C | 1 |
| Respiratory system; reproductive system | R |
| Methyl t-butyl ether (1634-04-4) | C | 8,000 |
| Kidney; eyes; alimentary system (liver) | R |
| Naphthalene (91-20-3) | C | 9 | Respiratory system | H | |
| Nickel & nickel compounds (except nickel oxide for chronic inhalation exposures) (Inhalation concentrations as µg Ni/m3: oral dose as µg Ni/kg-day) | A | 0.2[5] | Immune system | M | |
8 | 0.06[5] | Respiratory, immune systems | R | ||
C | 0.014[5] |
| Inhalation: Respiratory system; hematologic system Oral: Development | R | |
| Nickel oxide (1313-99-1) (Inhalation concentration as µg Ni/m3: oral dose as µg Ni/kg-day) | C | 0.02[5] | 11[5] | Inhalation: Respiratory system Oral: Development | M R |
| Nitric acid (7697-37-2) | A | 86 |
| Respiratory system | H |
| Nitrogen dioxide (10102-44-0) | A | 470 |
| Respiratory system | H |
| Ozone (10028-15-6) | A | 180 |
| Respiratory system; eyes | H |
| Perchloroethylene (127-18-4) (syn. Tetrachloroethylene)[3] | A | 20,000 | Nervous system; respiratory system; eyes | H | |
C | 35 | Kidney; alimentary system (liver) | M | ||
| Phenol (108-95-2) | A | 5,800 | Respiratory system; eyes | H | |
C | 200 | Alimentary system; cardiovascular system; kidney; nervous system | R | ||
| Phosgene (75-44-5) | A | 4 |
| Respiratory system | R |
| Phosphine (7803-51-2) | C | 0.8 |
| Respiratory system; alimentary system (liver); nervous system; kidney; hematologic system | M |
| Phosphoric acid (7664-38-2) | C | 7[4] |
| Respiratory system | R |
| Polychlorinated biphenyls (PCBs) Individual congeners evaluated using TEF methodology, relative to as 2,3,7,8-tetrachlorodibenzo-p-dioxin (see Appendix C in the TSD for Cancer Potency Factors | C | - | - | Inhalation & oral: Alimentary (liver) reproductive, endocrine, respiratory, hematologic systems; development | R |
| Phthalic anhydride (85-44-9) | C | 20 |
| Respiratory system | H |
| Propylene(115-07-1) | C | 3,000 |
| Respiratory system | R |
| Propylene glycol monomethyl ether (107-98-2) | C | 7,000 |
| Alimentary system (liver) | R |
| Propylene oxide (75-56-9) | A | 3,100 | Respiratory system; eyes; reproductive/development | H | |
C | 30 | Respiratory system | R | ||
| Selenium and selenium compounds (other than hydrogen selenide) | C | 20 | 5 | Inhalation & oral: Alimentary system (liver); cardiovascular system; nervous system | H |
| Silica (crystalline, respirable) | C | 3[4] |
| Respiratory system | H |
| Sodium hydroxide (1310-73-2) | A | 8 |
| Respiratory system; eyes; skin | H |
| Styrene (100-42-5) | A | 21,000 | Respiratory system; eyes; reproductive/development | H | |
C | 900[4] | Nervous system | H | ||
| Sulfates | A | 120 |
| Respiratory system | H |
| Sulfur dioxide (7446-09-5) | A | 660 |
| Respiratory system | H |
| Sulfuric acid (7664-93-9) [& oleum, acute only] | A | 120 | Respiratory system | H | |
C | 1 | Respiratory system | Mk | ||
| Toluene (108-88-3) | A | 5,000 | Respiratory, nervous systems; eyes | H | |
| 8 | 830 | Eyes | H | ||
C | 420 |
| Eyes | H | |
| Toluene diisocyanates: 2,4- (584-84-9)and 2,6- (91-08-7) isomers and mixed isomers (26471-62) | A | 2[5] | Respiratory system | H | |
| 8 | 0.015[5] | Respiratory system | H | ||
C | 0.008[5] |
| Respiratory system | H | |
| Trichloroethylene (79-01-6) | C | 600 |
| Nervous system; eyes | H |
| Triethylamine (121-44-8) | A | 2,800 | Nervous system; eyes | H | |
C | 200 | Eyes | R | ||
| Trimethylbenzenes (25551-13-7): 1,3,5- (108-67-8), 1,2,4- (95-63-6), 1,2,3- (526-73-8) | A | 2400[4, 5] |
| Nervous System | R |
8 | 8[4, 5] |
| Nervous system | R | |
C | 4[4, 5] |
| Nervous system | R | |
| Vanadium pentoxide(1314-62-1) | A | 30 |
| Respiratory system; eyes | H |
| Vinyl acetate (108-05-4) | C | 200 |
| Respiratory system | R, M |
| Vinyl chloride (75-01-4) | A | 180,000 |
| Nervous system; respiratory system; eyes | H |
| Xylenes: technical mixture (1330-20-7) and o-xylene (95-47-6), m-xylene (108-38-3) and p-xylene (106-42-3) isomers. | A | 22000 | Nervous & respiratory systems; eyes | H | |
C | 700 | Nervous & respiratory systems; eyes | H | ||
Footnotes:
[1]REL types: A = acute, 8 = 8-hour, C = chronic. Exposure averaging time for acute RELs is 1 hour. For 8-hour RELs, the exposure averaging time is 8 hours, which may be repeated. Chronic RELs are designed to address continuous exposures for up to a lifetime: the exposure metric used is the annual average exposure.
[2]Species used in key study for REL development: D = dog; Gb = gerbil; GP = guinea pig: H = human; Ha = hamster; M = mouse; Mk = monkey; R = rat; Rb = rabbit
[3]These peer-reviewed chronic REL values were developed under the Toxic Air Contaminant (TAC) Program mandated by AB1807.
[4]REL based on benchmark dose (BMC) approach.
[5]REL developed using the revised methodology (OEHHA, 2008)].